Fox Chase Cancer Center News

PHILADELPHIA, PA (March 6, 2014)—Stephen C. Rubin, MD, has joined the Department of Surgical Oncology at Fox Chase Cancer Center as Chief of Gynecologic Oncology, where he will specialize in the treatment of patients with gynecologic cancers—including ovarian, uterine, cervical, and endometrial. Dr. Rubin has also been named Co-Clinical Leader of the Gynecological Service Line and Professor in the clinical investigator track of the Department of Surgical Oncology. In addition, he will hold the Paul Grotzinger and Wilbur Raab Chair in Surgical Oncology.

PHILADELPHIA (February 21, 2014) – Accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT) signifies excellence in all quality aspects of patient care and collection practices related to cellular therapy treatments.

PHILADELPHIA, PA (February 20, 2014)—In the cells of humans and other organisms, only a subset of genes are active at any given time, depending largely on the stage of life and the particular duties of the cell. Cells use different molecular mechanisms to orchestrate the activation and deactivation of genes as needed. One central mechanism is an intricate DNA packaging system that either shields genes from activation or exposes them for use.

Proceeds from the carnival-inspired event will go toward research at Fox Chase

DOYLESTOWN, PA (February 4, 2014)—The Bucks County Chapter of Fox Chase Cancer Center’s Board of Associates will celebrate the excitement of Rio de Janeiro’s Carnival with the event “April in Rio” to be held on Saturday, April 12, 2014 from 6:30 to 10:30 p.m., at the James A. Michener Art Museum (138 South Pine Street in Doylestown, PA).  All money raised at the event will benefit research at Fox Chase Cancer Center.

PHILADELPHIA, PA (January 15, 2014) In his new roles, Beck will oversee all activities that support the academic and research operations of Fox Chase.

PHILADELPHIA, PA (January 7, 2014)  Fung will serve as Clinical Leader of the Blood Cancers Program and the Hematologic Oncology Service Line, and Professor of Medical Oncology. He will also be Director of the Temple University Hospital Bone Marrow Transplant Program.

PHILADELPHIA (January 7, 2014) – Larry R. Kaiser, MD, FACS, Dean of Temple University School of Medicine and President/CEO of Temple University Health System, of which Fox Chase is a part, has been appointed to the Governing Council of the American Hospital Association's Constituency Section for Health Care Systems. Appointed leaders represent premier health systems throughout the country.

PHILADELPHIA (December 12, 2013)—Researchers at Fox Chase Cancer Center are enrolling newly diagnosed breast cancer patients into a clinical trial of the promising drug reparixin, which targets tumors' ability to self-renew. The study, being presented at the 2013 San Antonio Breast Cancer Symposium, comes on the heels of research done in a Phase Ib pilot trial in which patients with metastatic disease take reparixin along with the chemotherapy drug paclitaxel (brand name Taxol), designed to assess the safety of dosage.